X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Johnson & Johnson Innovative Medicine has exercised the first of its options for an exclusive license to develop and commercialize novel target that aim to address unmet needs in immune-mediated disease, arising out of the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.
Lead Product(s): TRB-061
Therapeutic Area: Dermatology Product Name: TRB-061
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Collaboration leverages TRexBio’s Deep Biology platform, which mapsTreg behavior in human tissue to identify and target immune-regulatory pathways. Programs that have been identified and characterized leveraging TRex’s Deep Biology platform are TRB-031, TRB-041, and TRB-051.
Lead Product(s): TRB-051
Therapeutic Area: Immunology Product Name: TRB-051
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,155.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration January 09, 2023
Details:
Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in diseases, including its lead asset TRB-051.
Lead Product(s): TRB-051
Therapeutic Area: Immunology Product Name: TRB-051
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Polaris Partners
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
